We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
The impact of a cancer diagnosis can be stressful. Questions such as “how will I tell my family?”, “how will I afford to pay my bills?”, “will I ever work again?” and even “will I survive?” are at the forefront of the patient’s mind as they process their diagnosis and begin treatment. So, how can the patient experience with treatment be supported? By offering the best quality of care.
From 2012 to 2017, under the fifth authorization of the Prescription Drug User Fee Act (PDUFA V), FDA conducted 24 disease-specific Patient-Focused Drug Development (PFDD) meetings to systematically obtain the patient perspective on specific diseases and their treatments; both breast and lung cancer disease states have been the focus of the PFDD meetings held to date¹. The FDA also established the Oncology Excellence Committee in 2017, to facilitate the development and clinical review of oncology products by uniting scientific experts across the FDA’s product centers to conduct expedited review of drugs, biologics, and devices².
Never have the oncology patient’s unmet needs been more integrated in drug development than now.
Any chronic and acute IV therapies to treat cancer need to focus on the clinical outcomes, which may be influenced by the patient experience. Offering patients a choice in the way their treatment is administered is what patients are now expecting, including ways to disconnect a patient and their treatment from an IV pole. Large volume subcutaneous administration offers patients this option by allowing cancer medicines to be delivered in a clinic or non-clinic setting. This benefits the patient as it offers an alternative to frequent, time consuming and potentially expensive hospital visits. Using a combination of clinical and non-clinical settings, more patients can be treated in a 24-hour period.
West’s SmartDose® drug delivery platform improves the cancer patient experience by offering subcutaneous injection via a large volume device that attaches to the patient, without sacrificing quality of care.
With West’s SmartDose platform, you can expand patient access to subcutaneous injection as a treatment option. As West’s SmartDose injector is already approved for use with an approved drug and commercially available in the US, Europe and Japan, you can get to market quickly with a combination product that improves the way a treatment is delivered.
High-quality components and systems are critical in the market today, so we are constantly working by the side of our customers to ensure that their needs and, ultimately the patients' needs are met. We recently developed an oncology drug development-focused section on our website because we understand the challenges posed by packaging in this space and the requirements that need to be met.
Click here to learn more about our packaging and delivery solutions for challenges in oncology development.
SmartDose® is a registered trademark of West Pharma. Services IL, Ltd., a subsidiary of West Pharmaceutical Services, Inc.
West Pharmaceuticals will participate in two poster presentation sessions at the <a href="https://www.pda.org/"><span style="text-decoration: underline;">Parenteral Drug Association (PDA) Annual Meeting</span></a>, taking place March 16-18, 2015 in Las Vegas. During the meeting, West will also showcase innovations in integrated drug packaging and delivery systems that help ensure the quality, safety and efficacy of injectable drug products for pharmaceutical and biotechnology manufacturers worldwide at booth #405.
The number of biologic drug products marketed with an injection device has approximately quadrupled over the last decade. The growth in these drug therapies has been driven by several factors including new, self-administered therapies for chronic conditions such as rheumatoid arthritis and autoimmune diseases. In addition, injectable therapy is now being considered as a treatment for more conditions, including asthma and cholesterol problems.
<span style="color: #000000;">Container closure integrity is defined as the ability and quality of a container closure system to provide protection and maintain efficacy and sterility during the shelf life of a sterile drug product. The ability of rubber components to prevent microbial ingress of parenteral containers can be measured by seal integrity.</span>
We are excited to announce that thanks to the overwhelming support of our team members over the last 18 years, West’s donations to Camp Victory have now surpassed the $1 Million dollar mark! <br />Camp Victory, “a special place for special children,” is a camp located in Millville, PA (near West’s Jersey Shore and Williamsport sites) that serves as a fun camp retreat for children living with chronic health challenges. While at Camp Victory, a specialized staff ensures the children receive the greatest possible care, support and personal growth, while having much fun and making many friends.<br />Camp Victory hosted its first group of campers in 1994 and has grown steadily into the impressive facility and program it is today and has hosted over 30,000 overnight campers and counselors. Daily activities for campers include a variety of options, including archery, waterfront, challenge course, arts and crafts, and much more.
Automation is quickly becoming a major part of the world in which we live. From consumer applications like microwaves and automobiles, to use in large-scale factories that produce everything from dollar-store hair accessories to autopilot-driven aircrafts, automation surrounds us. This is a good thing – the products we use benefit from the increased quality, consistency, and productivity provided by automated systems.
English
Chinese
